Fundamental Analysis of ALTO NEUROSCIENCE INC(NYSE:ANRO) stock

Fundamental Rating

Taking everything into account, ANRO scores 2 out of 10 in our fundamental rating. ANRO was compared to 194 industry peers in the Pharmaceuticals industry. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.

In the past year ANRO has reported a negative cash flow from operations.

1.2 Ratios

ANRO has a Return On Assets of -41.91%. This is comparable to the rest of the industry: ANRO outperforms 44.27% of its industry peers.

Looking at the Return On Equity, with a value of -52.01%, ANRO is in line with its industry, outperforming 56.77% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-41.91%
ROE	-52.01%
ROIC	N/A

ROA(3y)-42.77%

ROA(5y)N/A

ROE(3y)-56.56%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ANRO has about the same amout of shares outstanding than it did 1 year ago.

The debt/assets ratio for ANRO has been reduced compared to a year ago.

2.2 Solvency

ANRO has an Altman-Z score of 2.35. This is not the best score and indicates that ANRO is in the grey zone with still only limited risk for bankruptcy at the moment.

ANRO has a Altman-Z score of 2.35. This is in the better half of the industry: ANRO outperforms 69.79% of its industry peers.

A Debt/Equity ratio of 0.14 indicates that ANRO is not too dependend on debt financing.

ANRO has a Debt to Equity ratio (0.14) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF	N/A
Altman-Z	2.35

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 15.22 indicates that ANRO has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 15.22, ANRO belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.

ANRO has a Quick Ratio of 15.22. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.

ANRO has a better Quick ratio (15.22) than 88.02% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.22
Quick Ratio	15.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ANRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.44%.

EPS 1Y (TTM)-31.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-46.2%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.79% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y43.58%

EPS Next 2Y17.82%

EPS Next 3Y6.79%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.82%

EPS Next 3Y6.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ANRO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALTO NEUROSCIENCE INC

NYSE:ANRO (11/22/2024, 1:10:41 PM)

4.35

+0.26 (+6.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap117.28M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-41.91%
ROE	-52.01%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.22
Quick Ratio	15.22
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-31.44%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y43.58%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ALTO NEUROSCIENCE INC (ANRO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens